| 1 | Biased signaling in GPCRs: Structural insights and implications for drug development. (Ma Y, Patterson B, Zhu L) Pharmacol Ther 2025 Feb;266:108786 |
| 2 | Fragment-based screening by protein-detected NMR spectroscopy. (Kerber PJ, Nuñez R, Jensen DR, Zhou AL, Peterson FC, Hill RB, Volkman BF, Smith BC) Methods Enzymol 2023;690:285-310 5 Citations |
| 5 | Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28. (Zhou AL, Jensen DR, Peterson FC, Thomas MA, Schlimgen RR, Dwinell MB, Smith BC, Volkman BF) SLAS Discov 2023 Jun;28(4):163-169 3 Citations |
| 1 | Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. (Aissa AF, Islam ABMMK, Ariss MM, Go CC, Rader AE, Conrardy RD, Gajda AM, Rubio-Perez C, Valyi-Nagy K, Pasquinelli M, Feldman LE, Green SJ, Lopez-Bigas N, Frolov MV, Benevolenskaya EV) Nat Commun 2021 Mar 12;12(1):1628 133 Citations |
| 4 | Recent Advances in Hypertension: Intersection of Metabolic and Blood Pressure Regulatory Circuits in the Central Nervous System. (Oliveira V, Kwitek AE, Sigmund CD, Morselli LL, Grobe JL) Hypertension 2021 Apr;77(4):1061-1068 21 Citations |
| 1 | An Overview of the Crystallized Structures of the SARS-CoV-2. (Ionescu MI) Protein J 2020 Dec;39(6):600-618 38 Citations |
| 2 | Serial Crystallography for Structure-Based Drug Discovery. (Zhu L, Chen X, Abola EE, Jing L, Liu W) Trends Pharmacol Sci 2020 Nov;41(11):830-839 14 Citations |
| 4 | Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus. (Kapoor A, Ghosh AK, Forman M, Hu X, Ye W, Southall N, Marugan J, Keyes RF, Smith BC, Meyers DJ, Ferrer M, Arav-Boger R) J Med Chem 2020 Apr 23;63(8):3896-3907 9 Citations |
| 1 | Structure-based discovery of potent and selective melatonin receptor agonists. (Patel N, Huang XP, Grandner JM, Johansson LC, Stauch B, McCorvy JD, Liu Y, Roth B, Katritch V) Elife 2020 Mar 02;9 29 Citations |
| 4 | High-Throughput Screening of NOX Inhibitors. (Zielonka J, Zielonka M, Cheng G, Hardy M, Kalyanaraman B) Methods Mol Biol 2019;1982:429-446 12 Citations |
| 1 | Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists. (Girdhar K, Dehury B, Kumar Singh M, Daniel VP, Choubey A, Dogra S, Kumar S, Mondal P) J Biomol Struct Dyn 2019 Sep;37(15):3976-3986 32 Citations |
| 1 | Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. (Rosati R, Polin L, Ducker C, Li J, Bao X, Selvakumar D, Kim S, Xhabija B, Larsen M, McFall T, Huang Y, Kidder BL, Fribley A, Saxton J, Kakuta H, Shaw P, Ratnam M) Clin Cancer Res 2018 Dec 15;24(24):6509-6522 14 Citations |
| 1 | Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. (Tan L, Yan W, McCorvy JD, Cheng J) J Med Chem 2018 Nov 21;61(22):9841-9878 98 Citations |
| 1 | High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis. (Favari E, Thomas MJ, Sorci-Thomas MG) J Cardiovasc Pharmacol 2018 Jun;71(6):325-331 35 Citations |
| 3 | Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy. (Egner JM, Jensen DR, Olp MD, Kennedy NW, Volkman BF, Peterson FC, Smith BC, Hill RB) Chembiochem 2018 Mar 02;19(5):448-458 11 Citations |
| 1 | Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs. (McCorvy JD, Butler KV, Kelly B, Rechsteiner K, Karpiak J, Betz RM, Kormos BL, Shoichet BK, Dror RO, Jin J, Roth BL) Nat Chem Biol 2018 Feb;14(2):126-134 137 Citations |
| 1 | High Content Screening of Mammalian Primary Cortical Neurons. (Motti D, Blackmore M, Bixby JL, Lemmon VP) Methods Mol Biol 2018;1683:293-304 |
| 5 | A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB) Redox Biol 2018 Apr;14:316-327 190 Citations |
| 1 | Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A. (Jacobson AR, Adler M, Silvaggi NR, Allen KN, Smith GM, Fredenburg RA, Stein RL, Park JB, Feng X, Shoemaker CB, Deshpande SS, Goodnough MC, Malizio CJ, Johnson EA, Pellett S, Tepp WH, Tzipori S) Toxicon 2017 Oct;137:36-47 11 Citations |
| 2 | Primary Human Lung Alveolus-on-a-chip Model of Intravascular Thrombosis for Assessment of Therapeutics. (Jain A, Barrile R, van der Meer AD, Mammoto A, Mammoto T, De Ceunynck K, Aisiku O, Otieno MA, Louden CS, Hamilton GA, Flaumenhaft R, Ingber DE) Clin Pharmacol Ther 2018 Feb;103(2):332-340 257 Citations |
| 1 | A Hexasaccharide Containing Rare 2-O-Sulfate-Glucuronic Acid Residues Selectively Activates Heparin Cofactor II. (Sankarayanarayanan NV, Strebel TR, Boothello RS, Sheerin K, Raghuraman A, Sallas F, Mosier PD, Watermeyer ND, Oscarson S, Desai UR) Angew Chem Int Ed Engl 2017 Feb 20;56(9):2312-2317 53 Citations |
| 1 | Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists. (Chen X, McCorvy JD, Fischer MG, Butler KV, Shen Y, Roth BL, Jin J) J Med Chem 2016 Dec 08;59(23):10601-10618 47 Citations |
| 1 | Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists. (Cheng J, McCorvy JD, Giguere PM, Zhu H, Kenakin T, Roth BL, Kozikowski AP) J Med Chem 2016 Nov 10;59(21):9866-9880 29 Citations |
| 1 | Structure-based discovery of opioid analgesics with reduced side effects. (Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang XP, Sassano MF, Giguère PM, Löber S, Da Duan, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK) Nature 2016 Sep 08;537(7619):185-190 742 Citations |
| 1 | Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. (Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH) EBioMedicine 2016 Jun;8:117-131 82 Citations |
| 1 | Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. (Sayed N, Liu C, Wu JC) J Am Coll Cardiol 2016 May 10;67(18):2161-2176 222 Citations |
| 1 | Experimental Models of Anxiety for Drug Discovery and Brain Research. (Hart PC, Bergner CL, Smolinsky AN, Dufour BD, Egan RJ, LaPorte JL, Kalueff AV) Methods Mol Biol 2016;1438:271-91 17 Citations |
| 1 | Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. (Maddocks K, Jones JA) Semin Oncol 2016 Apr;43(2):251-9 26 Citations |
| 1 | Creating Patient-Specific Neural Cells for the In Vitro Study of Brain Disorders. (Brennand KJ, Marchetto MC, Benvenisty N, Brüstle O, Ebert A, Izpisua Belmonte JC, Kaykas A, Lancaster MA, Livesey FJ, McConnell MJ, McKay RD, Morrow EM, Muotri AR, Panchision DM, Rubin LL, Sawa A, Soldner F, Song H, Studer L, Temple S, Vaccarino FM, Wu J, Vanderhaeghen P, Gage FH, Jaenisch R) Stem Cell Reports 2015 Dec 08;5(6):933-945 68 Citations |
| 1 | The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. (Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R) Clin Cancer Res 2015 Oct 15;21(20):4561-8 28 Citations |
| 1 | Ergot Alkaloids (Re)generate New Leads as Antiparasitics. (Chan JD, Agbedanu PN, Grab T, Zamanian M, Dosa PI, Day TA, Marchant JS) PLoS Negl Trop Dis 2015;9(9):e0004063 21 Citations |
| 1 | Discovery of a selective, safe and novel anti-malarial compound with activity against chloroquine resistant strain of Plasmodium falciparum. (Agarwal A, Paliwal S, Mishra R, Sharma S, Kumar Dwivedi A, Tripathi R, Gunjan S) Sci Rep 2015 Sep 08;5:13838 14 Citations |
| 1 | Recently disclosed chemical entities as potential candidates for management of tuberculosis. (Stec J, Abourashed EA) Pharm Pat Anal 2015;4(4):317-47 3 Citations |
| 1 | Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. (Andreev IA, Manvar D, Barreca ML, Belov DS, Basu A, Sweeney NL, Ratmanova NK, Lukyanenko ER, Manfroni G, Cecchetti V, Frick DN, Altieri A, Kaushik-Basu N, Kurkin AV) Eur J Med Chem 2015;96:250-8 26 Citations |
| 1 | TPL2 kinase regulates the inflammatory milieu of the myeloma niche. (Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F) Blood 2014 May 22;123(21):3305-15 84 Citations |
| 1 | Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. (Guan X, Mack DL, Moreno CM, Strande JL, Mathieu J, Shi Y, Markert CD, Wang Z, Liu G, Lawlor MW, Moorefield EC, Jones TN, Fugate JA, Furth ME, Murry CE, Ruohola-Baker H, Zhang Y, Santana LF, Childers MK) Stem Cell Res 2014 Mar;12(2):467-80 108 Citations |
| 1 | Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. (McGivern JV, Ebert AD) Adv Drug Deliv Rev 2014 Apr;69-70:170-8 23 Citations |
| 1 | Malfolded protein structure and proteostasis in lung diseases. (Balch WE, Sznajder JI, Budinger S, Finley D, Laposky AD, Cuervo AM, Benjamin IJ, Barreiro E, Morimoto RI, Postow L, Weissman AM, Gail D, Banks-Schlegel S, Croxton T, Gan W) Am J Respir Crit Care Med 2014 Jan 01;189(1):96-103 57 Citations |
| 1 | A PET-compatible tissue bioreactor for research, discovery, and validation of imaging biomarkers and radiopharmaceuticals: system design and proof-of-concept studies. (Whitehead TD, Nemanich ST, Dence C, Shoghi KI) J Nucl Med 2013 Oct;54(10):1812-9 4 Citations |
| 1 | Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. (Gameiro SR, Jammeh ML, Hodge JW) Expert Rev Vaccines 2013 Jun;12(6):617-29 14 Citations |
| 1 | Fool's gold, lost treasures, and the randomized clinical trial. (Stewart DJ, Kurzrock R) BMC Cancer 2013 Apr 16;13:193 48 Citations |
| 1 | High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probe. (McCallum MM, Nandhikonda P, Temmer JJ, Eyermann C, Simeonov A, Jadhav A, Yasgar A, Maloney D, Arnold AL) J Biomol Screen 2013 Jul;18(6):705-13 24 Citations |
| 1 | The future of neurodegenerative diseases: emerging targets, treatments and technologies. (Voss J, Ebert A, Wolfe M, Lindsley C, Cookson M, Deane R) Future Med Chem 2012 Sep;4(13):1661-9 2 Citations |
| 1 | Modeling neurodegenerative diseases using stem cells: is it accelerating drug discovery? (Ebert AD) Future Med Chem 2012 Sep;4(13):1651-3 1 Citation |
| 1 | Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. (Mysinger MM, Weiss DR, Ziarek JJ, Gravel S, Doak AK, Karpiak J, Heveker N, Shoichet BK, Volkman BF) Proc Natl Acad Sci U S A 2012 Apr 03;109(14):5517-22 128 Citations |
| 1 | Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound. (Mueller R, Dawson ES, Meiler J, Rodriguez AL, Chauder BA, Bates BS, Felts AS, Lamb JP, Menon UN, Jadhav SB, Kane AS, Jones CK, Gregory KJ, Niswender CM, Conn PJ, Olsen CM, Winder DG, Emmitte KA, Lindsley CW) ChemMedChem 2012 Mar 05;7(3):406-14 40 Citations |
| 2 | Unique ganglioside binding by botulinum neurotoxins C and D-SA. (Kroken AR, Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT) FEBS J 2011 Dec;278(23):4486-96 23 Citations |
| 1 | Natural Products Genomics: A novel approach for the discovery of anti-cancer therapeutics. (Monks NR, Li B, Gunjan S, Rogers DT, Kulshrestha M, Falcone DL, Littleton JM) J Pharmacol Toxicol Methods 2011;64(3):217-25 11 Citations |
| 2 | Binding site identification and structure determination of protein-ligand complexes by NMR a semiautomated approach. (Ziarek JJ, Peterson FC, Lytle BL, Volkman BF) Methods Enzymol 2011;493:241-75 61 Citations |
| 1 | Asparaginyl-tRNA synthetase pre-transfer editing assay. (Danel F, Caspers P, Nuoffer C, Härtlein M, Kron MA, Page MG) Curr Drug Discov Technol 2011 Mar;8(1):66-75 17 Citations |
| 1 | Development of novel therapies for hepatitis C. (Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA) Antiviral Res 2010 Apr;86(1):79-92 73 Citations |
| 1 | Human stem cells and drug screening: opportunities and challenges. (Ebert AD, Svendsen CN) Nat Rev Drug Discov 2010 May;9(5):367-72 148 Citations |
| 1 | Structure-based drug design and modern medicine. (Vijayakrishnan R) J Postgrad Med 2009;55(4):301-4 36 Citations |
| 1 | Experimental models of anxiety for drug discovery and brain research. (Hart PC, Bergner CL, Smolinsky AN, Dufour BD, Egan RJ, Laporte JL, Kalueff AV) Methods Mol Biol 2010;602:299-321 45 Citations |
| 1 | Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. (Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, Elsohly MA) Recent Pat CNS Drug Discov 2009 Jun;4(2):112-36 39 Citations |
